[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350812-105":59,"doc-detail-350812-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","beyond-ca-125-circulating-cell-free-dna-as-the-next-generation-biomarker-in-ovarian-malignancy-research-open-access","Beyond CA-125 - Circulating Cell-Free DNA as the Next-Generation Biomarker in Ovarian Malignancy - Research Open Access","","Ovarian cancer remains difficult to screen and lacks biomarkers with consistently high sensitivity and specificity, contributing to high mortality. This case-control prospective study evaluates circulating cell-free DNA (cfDNA) as a non-invasive biomarker. Among 150 participants (50 malignant, 50 benign lesions, 50 controls), cfDNA quantification used real-time PCR. Malignant patients showed higher cfDNA, with ROC performance supporting diagnostic, stage-discrimination, prognostic, and mortality prediction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/beyond-ca-125-circulating-cell-free-dna-as-the-next-generation-biomarker-in-ovarian-malignancy-research-open-access/350812/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/beyond-ca-125-circulating-cell-free-dna-as-the-next-generation-biomarker-in-ovarian-malignancy-research-open-access/350812.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in ovarian cancer detection?","Question",{"text":112,"@type":113},"It addresses the lack of efficient screening methods and trustworthy biomarkers with high sensitivity and specificity, which limits early detection and contributes to high death rates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was cfDNA measured and what study design was used?",{"text":117,"@type":113},"A case-control prospective study was conducted with 150 participants. cfDNA was quantified using real-time PCR, followed by clinical, laboratory, and imaging evaluation and survival analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about cfDNA in malignant versus benign and control groups?",{"text":121,"@type":113},"Mean cfDNA was markedly higher in the malignant group than in benign lesion and control groups. ROC analysis supported its diagnostic discrimination and its association with late stage and mortality risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350812,1790903170,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Elgedawy et al. BMC Cancer (2026) 26:1088 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15967-7](https://doi.org/10.1186/s12885-026-15967-7)  \nRESEARCH Open Access  \nBeyond CA-125: circulating cell-free DNA asthe next-generation biomarker in ovarian malignancy  \nGamalat A. Elgedawy 1, Rasha A. Adbelmoneum2, Amira I. Aldesoky2, Samya S. Mashal3, Amany E. Awad4, Naglaa S. Elabd5* and Marwa L. Helal 1  \nAbstract  \nBackground and aims Due to a lack of efficient screening methods or trustworthy biomarkers with high sensitivity and specificity, ovarian cancer (OC) is a quarrelsome disease with a high death rate. Investigators believe that circulating tumor cell-free DNA (cfDNA) can provide crucial clues concerning both primary and metastatic OCs. Our goal was to identify the potential of circulating cfDNA as a non-invasive biomarker for ovarian cancer.  \nPatients and methods This case‒control prospective study was carried out on 150 participants, of whom 50 patients were confirmed to have ovarian cancer, 50 patients had benign ovarian lesions, and 50 participants  \nwere controls. For OC patients, medical, laboratory, and imaging evaluations together with survival analysis were performed. Quantification of cfDNA was done by real-time PCR.  \nResults A distinct difference in the mean cfDNA was observed in the malignant group (11 . 84 ng/mL) compared to the benign (3 .90 ng/mL) and control (0 .23 ng/mL) groups. ROC curve analysis revealed that cfDNA had the highest value as a strong discriminatory marker for prediction of ovarian cancer in suspected cases and prediction of late stage and is a reasonable predictor of mortality (AUC 0 . 934, p \u003C 0. 001, 95% CI: 0 .881–0. 986; AUC 0 . 993, p \u003C 0. 001, 95% CI: 0 .978–1. 0; and AUC 0 . 814, p = 0 . 001, 95% CI: 0 .690–0. 937) . The multivariate logistic regression reinforces its independent prognostic value for progression-free survival and overall survival.  \nConclusion Our results indicate that cfDNA has a strong correlation with tumor grade and predictive capability in Cox models, suggesting that it may serve as a diagnostic and prognostic biomarker for OC. In clinical setting, these findings support the use of cfDNA in OC risk stratification and treatment planning, potentially enabling aggressive therapies for patients with high cfDNA expression.  \nKeywords Biomarker, cfDNA, Ovarian cancer, Prognosis  \n*Correspondence: Naglaa S. Elabd  \n[naglaa.alabd.12@med.menofia.edu.eg](naglaa.alabd.12@med.menofia.edu.eg); naglaa_[elabd@yahoo.com](elabd@yahoo.com)  \n1Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebin ElKoum, Menoufia, Egypt 2Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Shebin ElKoum, Menoufia, Egypt  \n3Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebin ElKoum, Menoufia, Egypt  \n4Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Shebin ElKoum, Menoufia, Egypt 5Depatment of Tropical medicine, Faculty of Medicine, Menoufia University, Shebin ElKoum, Menoufia, Egypt  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation ","cbCaikcMqT96lsM0","https://ap.wps.com/l/cbCaikcMqT96lsM0","pdf",1624506,13,"English","# Abstract\n## Background and aims\n## Patients and methods\n## Results\n## Conclusion\n# Background","[{\"question\":\"What problem does the study address in ovarian cancer detection?\",\"answer\":\"It addresses the lack of efficient screening methods and trustworthy biomarkers with high sensitivity and specificity, which limits early detection and contributes to high death rates.\"},{\"question\":\"How was cfDNA measured and what study design was used?\",\"answer\":\"A case-control prospective study was conducted with 150 participants. cfDNA was quantified using real-time PCR, followed by clinical, laboratory, and imaging evaluation and survival analysis.\"},{\"question\":\"What did the results show about cfDNA in malignant versus benign and control groups?\",\"answer\":\"Mean cfDNA was markedly higher in the malignant group than in benign lesion and control groups. ROC analysis supported its diagnostic discrimination and its association with late stage and mortality risk.\"}]","Beyond CA-125 - Circulating Cell-Free DNA as the Next-Generation Biomarker in Ovarian Malignancy - Research Open Access | PDF",1790091246,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43f6fdf710a14661185280bc150c4a62.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05d0b8f897fd724f7492fcdc80ea6848.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afb8e406e596297657f0493295723b00.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1be49d79b160039c1ab218819bb37b29.webp",980,1306]